Form 4: Director Karimah Es Sabar Granted CAPR Stock Options

Capricor Therapeutics director Karimah Es Sabar was granted 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Summary

• Karimah Es Sabar, a Director of Capricor Therapeutics, Inc. (CAPR), was granted 15,500 stock options.
• The options have an exercise price of $24.81 per share.
• The grant date for the transaction was January 5, 2026.
• The options will vest at a rate of 1/12th on the first day of each month, commencing February 1, 2026, and will be fully vested by December 31, 2026.
• The expiration date for these options is January 5, 2036.
• This award is for annual board service.
• The option allows for early exercise, meaning shares can be purchased prior to vesting, but these shares would be restricted and subject to repurchase by the Issuer if service terminates before full vesting.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued board engagement and alignment with shareholder interests, though it's a routine compensation event rather than a significant operational announcement.

Positives

• The grant of stock options aligns the director's interests with shareholder value.
• The options are part of annual board service compensation, indicating ongoing commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of Capricor Therapeutics' stock price. If the stock price does not exceed the exercise price of $24.81, the options may expire worthless.
• Early exercise of options carries the risk of restricted stock subject to repurchase by the Issuer if service terminates prior to vesting.

Future Outlook

The grant of stock options to a director for annual board service suggests an expectation of continued board oversight and strategic contribution from Karimah Es Sabar. The vesting schedule incentivizes long-term engagement.

Industry Context

This is a standard equity compensation practice for directors in publicly traded companies, aligning their interests with long-term shareholder value. It reflects typical corporate governance practices for incentivizing board members, particularly in the biotechnology sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a common practice across the biotechnology and pharmaceutical industries, similar to companies like Moderna (MRNA) or Pfizer (PFE) which use equity awards to incentivize leadership.
• The vesting schedule (monthly over a year) is typical for annual grants, ensuring continued service.
• The exercise price being set at the market price on the grant date (implied by a $0 derivative price and an exercise price) is standard for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity compensation, potentially leading to better long-term decision-making.

Next Steps

• The director will continue to serve on the board of Capricor Therapeutics.
• The stock options will begin vesting on February 1, 2026, and continue monthly until fully vested by December 31, 2026.
• The director may choose to exercise the options at any time before the expiration date of January 5, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their annual compensation. While it indicates continued board engagement and alignment of interests, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Capricor Therapeutics, CAPR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Karimah Es Sabar